Publications by authors named "Yuliya Volchek"
Article Synopsis
- - The study highlights how massive parallel sequencing (MPS) is used to detect rare mutations in a chronic myeloid leukaemia (CML) patient that can lead to resistance against therapy with tyrosine kinase inhibitors.
- - MPS improves sensitivity in identifying mutations by analyzing large volumes of sequencing data, allowing for the monitoring of mutation frequency over time, including the resistance-associated ABL1 T315I mutation.
- - The research also finds a correlation between the appearance of adjacent mutations and provides a method for detecting low-frequency mutations, which could be crucial for advancing clinical applications of sequencing technologies.
Imatinib (IM) is the current first line treatment for chronic myeloid leukemia (CML). However, the disease will progress in the majority of patients pausing IM. IFN-α may intensify the response and increase the percentage of patients maintaining remission after IM cessation.
View Article and Find Full Text PDF